Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Curcumin
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vascarta Commences a Phase I Clinical Study of VAS101 in Osteoarthritis
Details : VAS101 is a highly concentrated curcumin gel formulation that employs a patented topical/transdermal delivery platform. It is being evaluated for the treatment of knee osteoarthritis.
Product Name : VAS101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 18, 2025
Lead Product(s) : Curcumin
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gemcitabine,Curcumin
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : CUNY
Deal Size : Undisclosed
Deal Type : Collaboration
Vascarta and CUNY Collaborate to Improve Chemotherapy Efficacy and Safety
Details : The collaboration aims to advance the clinical development of a therapy that links anti-cancer agents, such as Gemzar (gemcitabine), with curcumin to enhance the effectiveness in treating cancer.
Product Name : Gemzar
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
January 13, 2025
Lead Product(s) : Gemcitabine,Curcumin
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : CUNY
Deal Size : Undisclosed
Deal Type : Collaboration